>_ QFI Terminal
TerminalStocks › XRTX

XORTX Therapeutics Inc. (XRTX) Stock

Healthcare · Biotechnology · CA
$2.07 +24.40%
Last updated Sep 20, 2026 15:00 UTC

XRTX Key Statistics

Market Cap$575,079.79
P/E (TTM)-0.13
P/S (TTM)
P/B (TTM)0.19
Revenue (TTM)$0.00
EPS (TTM)$-16.00
Dividend Yield
ROE (TTM)-111.11%
Net Margin0.00%
Gross Margin0.00%
52W High$3.60
52W Low$1.59
Analyst View
Price Target
Employees2
Volume5,022,005

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

CEO: Allen Warren Davidoff. Company website

XRTX — Frequently Asked Questions

What is the XRTX stock price today?

XORTX Therapeutics Inc. (XRTX) trades at $2.07, up 24.40% on the day, as of Sep 20, 2026 15:00 UTC.

What is XORTX Therapeutics Inc.'s market cap?

XORTX Therapeutics Inc. has a market capitalisation of $575,079.79, calculated from the live XRTX share price and shares outstanding.

What is the P/E ratio of XRTX?

XRTX has no meaningful price-to-earnings ratio: XORTX Therapeutics Inc. lost $16.00 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does XORTX Therapeutics Inc. make?

XORTX Therapeutics Inc. generated revenue of $0.00 over the trailing twelve months.

What is the 52-week range for XRTX?

XRTX has traded between $1.59 and $3.60 over the past 52 weeks, and the last price is 42.6% below that high.

Is XORTX Therapeutics Inc. profitable?

Yes. XORTX Therapeutics Inc. keeps 0.00% of revenue as net income over the trailing twelve months.

What sector is XORTX Therapeutics Inc. in?

XORTX Therapeutics Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in CA .

Who is the CEO of XORTX Therapeutics Inc.?

Allen Warren Davidoff is the chief executive of XORTX Therapeutics Inc., which employs 2 people.

Where can I track XRTX in real time?

QFI Terminal shows XRTX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See XRTX live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open XRTX in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG ARGX argenx SE INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc GMAB Genmab A/S

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.